Monitor upcoming CTIM-76 Phase 1a data in June 2026 and CT-95 data in September 2026 as primary catalysts. The EPS beat is modest given pre-revenue status; stock movement will likely hinge on clinical data rather than financials.
Price Chart
Executive Summary
Context Therapeutics reported Q1 2026 EPS of -$0.09, beating consensus of -$0.12 by 25%. The pre-revenue biotech highlighted upcoming clinical catalysts, including Phase 1a data for CTIM-76 in June 2026, while cash burn increased. Net loss widened to $8.7M vs $4.6M a year ago, with cash of $54.5M expected to fund operations into mid-2027.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.09 vs consensus -$0.12 (beat by $0.03, +25%)
- Net loss $8.7M vs $4.6M in Q1 2025
- Cash and equivalents $54.5M, down from $66.0M at year-end 2025
- R&D expenses $7.0M, nearly doubled from $3.5M a year ago
- FDA granted Fast Track Designation for CTIM-76 in April 2026
- Phase 1a interim data for CTIM-76 expected June 2026; CT-95 data expected September 2026
- CT-202 Phase 1 initiation expected Q3 2026
Financial Impact
EPS beat of $0.03 vs consensus; net loss increased to $8.7M from $4.6M
Risk Factors
- Clinical trial failure for CTIM-76 or other pipeline candidates
- Cash burn accelerated; may require dilutive financing if data readouts delay
- No approved products; revenue growth not expected in near term
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289410 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 15, 2026 19w ago | 8-K | $0.6791 $0.6299 | ▼ −7.24% | ▼ −5.86% | $0.2400 (−64.66%) |
Jun 15, 2026 19w ago | Press Release | $0.6791 $0.6299 | ▼ −7.24% | ▼ −5.86% | $0.2400 (−64.66%) |
May 18, 2026 23w ago | PRESS-RELEASE / 8-K | $2.15 $2.63 | ▲ +22.33% | ▲ +20.71% | $0.2400 (−88.84%) |
May 6, 2026 24w ago | Press Release | $2.33 $2.36 | ▲ +1.29% | ▼ −0.22% | $0.2400 (−89.70%) |
May 1, 2026 25w ago | 8-K | $2.30 $2.39 | ▲ +3.91% | ▲ +0.98% | $0.2400 (−89.57%) |
Apr 2, 2026 29w ago | 8-K | $2.72 $2.49 | ▼ −8.46% | ▼ −12.07% | $0.2400 (−91.18%) |
Mar 23, 2026 31w ago | Press Release | $3.18 $2.62 | ▼ −17.61% | ▼ −17.19% | $0.2400 (−92.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers